Related references
Note: Only part of the references are listed.Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies
A. Freites-Martinez et al.
ACTAS DERMO-SIFILIOGRAFICAS (2021)
Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Kirsi M. Manz et al.
ADVANCES IN THERAPY (2020)
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Brian I. Rini et al.
LANCET ONCOLOGY (2020)
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Robert J. Motzer et al.
CANCER (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Andrew W. Hahn et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Christopher J. D. Wallis et al.
EUROPEAN UROLOGY (2018)
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
Jun Guo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M. Gross-Goupil et al.
ANNALS OF ONCOLOGY (2018)
Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma
Rana R. McKay et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MET Inhibition in Clear Cell Renal Cell Carcinoma
Zuoquan Xie et al.
JOURNAL OF CANCER (2016)
Network Meta-Analysis Using R: A Review of Currently Available Automated Packages
Binod Neupane et al.
PLOS ONE (2014)
ADDIS: A decision support system for evidence-based medicine
Gert van Valkenhoef et al.
DECISION SUPPORT SYSTEMS (2013)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer
Hung-Jui Tan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Checking consistency in mixed treatment comparison meta-analysis
S. Dias et al.
STATISTICS IN MEDICINE (2010)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Targeting von Hippel-Lindau pathway in renal cell carcinoma
Premal H. Patel et al.
CLINICAL CANCER RESEARCH (2006)
Assessing evidence inconsistency in mixed treatment comparisons
Guobing Lu et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2006)
Share Paper
